HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $50 price target.

April 04, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Genmab with a $50 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to an uptick in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100